SHAH ALAM:Pharmaniaga Bhd (Pharmaniaga) assures the COVID-19 vaccine, CoronaVac produced by Chinese pharmaceutical company, Sinovac Life Sciences Co Ltd (Sinovac), is safe, effective and halal.
Pharmaniaga Research and Development Division head, Dr Badarulhisam Abdul Rahman, said the vaccine produced using inactive virus technology is the most effective and proven method for the past 40 years.
"The same method is also used for the production of vaccines for dangerous diseases such as Polio and Hepatitis A. This technology has proven to be effective compared to other new technologies whose risks are not yet known," he said when presenting the development of the vaccine virtually, today.
Also participating in the presentation session was Pharmaniaga Group managing director, Datuk Zulkarnain Md Eusope.
However, Dr Badarulhisam said confusion about the effectiveness of the vaccine arose after clinical studies in the two countries showed Turkey had a score of 91.25 per cent while Brazil had 50.38 per cent.
He explained that the study in Turkey can be seen as a benchmark for the effectiveness of the CoronaVac vaccine because it was tested on the general population involving 13,000 individuals aged 18 and above compared to Brazil which tested it on 13,060 health workers exposed to the COVID-19 virus daily.
"However, the study in Turkey will only be completed early this month. But we believe that the level of effectiveness will exceed 90 per cent, which is above the 50 per cent standard set by the World Health Organisation (WHO) for a vaccine to be registered," he said.
Dr Badarulhisam added that through the clinical study, no serious side effects including 'Vaccine Enhance Disease' were detected after two doses of the vaccine were given to the participants and the majority only experienced mild reactions.
In the meantime, Zulkarnain said Pharmaniaga had researched the contents, formulas and methods the vaccine was produced and was confident that it was halal to use as stated by the Indonesian Ulamak Council.
He also expects the CoronaVac vaccine to be approved by the National Pharmaceutical Regulatory Division (NPRA) by the end of this month or early March before being distributed in April.
"According to the agreement, Pharmaniaga will supply 12 million doses of this vaccine. In the first month, we will supply one million doses of CoronaVac vaccine followed by two million doses in the next month to be distributed by the government," he said.
Asked whether Pharmaniaga might sell the vaccine to the private sector, especially to industries for the use of their foreign workers, Zulkarnain said the matter was discussed with the government.
"We are currently in talks with the government (to sell CoronaVac) because after supplying 12 million doses of the vaccine, Pharmaniaga will still have a supply of another two million doses. However, the government has requested that the vaccine be given to government-linked companies (GLCs) which are 'economic fronliners' as well as foreign workers and expatriates.
"Pharmaniaga is also gathering information about it and once completed, we will negotiate how it will be carried out. However, the distribution of vaccines for Malaysians is our priority at this time," he said.
On Jan 12, Pharmaniaga signed an agreement with Sinovac to supply 14 million doses of the COVID-19 vaccine, the bottling process of which was done at a high-tech factory in Puchong, Selangor.
On Jan 26, Pharmaniaga signed an agreement to supply 12 million doses of CoronaVac COVID-19 vaccine to the Ministry of Health Malaysia.
-- BERNAMA
Bernama
Tue Feb 02 2021
On Jan 12, Pharmaniaga signed an agreement with Sinovac to supply 14 million doses of the COVID-19 vaccine, the bottling process of which was done at a high-tech factory in Puchong, Selangor. - File picture/ Reuters
Keupayaan merancang, melaksanakan reformasi dasar negara
Bagaimana dinamika ekonomi, sosial dan budaya semasa dalam mempengaruhi pembangunan dan transformasi negara seperti Malaysia? Kupasa bersama Ketua Ekonomi Buruh, Kementerian Sumber Manusia dan Emiratis, UAE, Prof Madya Dr. Mohd Yusof Saari.
OPR: Pengaruh keputusan bank pusat Asia lain
Pakar Ekonomi, Prof Emeritus Dr Barjoyai Bardai berkongsi pandangan berkenaan unjuran kadar dasar semalaman (OPR) yang dijadualkan pada 8-9 Mei 2024.
AWANI Ringkas: Goldman Sachs selesai membayar penalti AS$2.9 bilion
Ikuti rangkuman berita utama yang menjadi tumpuan sepanjang hari di Astro AWANI menerusi AWANI Ringkas.
Perdana Menteri akan bertemu Petronas untuk bincang mengenai projek di Pengerang
Beliau berkata terdapat satu lagi aspek yang perlu dibincangkan berhubung komitmen Saudi Aramco memperluas fasiliti di Pengerang.
“Arwah Hail Amir mesra orangnya, mudah berkawan” - Chuari Selamat
Suatu hal yang istimewa mengenai Hail Amir ialah beliau tidak pernah sesekali lupa menghargai komposer dan penulis lirik, kata Chuari.
Ayat 'jika PH ditakdirkan menang' bayangkan moral dan semangat PN runtuh - Fahmi
Katanya, ayat berkenaan juga seolah-olah membayangkan bahawa PN sedia mengaku kalah pada PRK DUN Kuala Kubu Baharu, Sabtu ini.
HSBC yakin Malaysia tidak mungkin ikut langkah Indonesia, Filipina naikkan kadar faedah
Bank Negara Malaysia (BNM) tidak mungkin mengikuti rakan bank pusat di Indonesia dan Filipina dalam menaikkan kadar faedah apabila jawatankuasa dasar monetarinya bermesyuarat minggu ini, kata HSBC.
Jualan Proton meningkat 17 peratus pada bulan lalu
Pengeluar kereta nasional itu berkata jualan bagi empat bulan pertama tahun ini turut meningkat kukuh kepada 50,175 unit berbanding 49,702 unit yang dijual dalam tempoh yang sama tahun lalu, katanya dalam satu kenyataan hari ini.
Harga koko tinggi berpotensi beri pulangan besar kepada lebih 5,000 pekebun kecil koko - Johari Ghani
Kerajaan akan menyalurkan peruntukan RM9.5 juta untuk pelaksanaan projek penanaman koko dan pemulihan ladang koko. Menteri Perladangan dan Komoditi, Datuk Seri Johari Abdul Ghani berkata, penanaman koko baharu akan meliputi kawasan seluas 350 hektar manakala projek pemulihan ladang koko akan merangkumi kawasan seluas 2,126 hektar.
Shell bincang jual stesen minyak di Malaysia kepada Saudi Aramco - Sumber
Rundingan bermula pada akhir 2023 dan perjanjian mungkin dimuktamadkan dalam beberapa bulan akan datang, kata satu sumber. Dua sumber yang diberi taklimat mengenai perkara itu meletakkan potensi saiz urus niaga pada kira-kira RM4 bilion hingga RM5 bilion ringgit ($844 juta hingga $1.06 bilion).
CITF-C perinci pemberian vaksin Sinovac untuk kanak-kanak
Perincian perihal pemberian vaksin Sinovac kepada kanak-kanak berumur lima hingga 11 tahun akan diputuskan selepas mesyuarat Jawatankuasa Bertindak Imunisasi COVID-19 Kanak-Kanak (CITF-C) malam ini.
Sinovac antara vaksin paling selamat untuk golongan pediatrik - Pharmaniaga
Golongan kanak-kanak dan remaja perlu divaksin untuk mengecilkan lagi risiko permutasian dan kebolehjangkitan virus COVID-19 dalam masyarakat.
Kajian terbaharu tiga dos vaksin Sinovac COVID-19 berkesan ke atas Omicron
Data penyelidikan terbaharu diterbitkan Sinovac Biotech Ltd menunjukkan bahawa tiga dos vaksin Sinovac COVID-19 menghasilkan antibodi peneutral yang lebih tinggi dalam 95 peratus penerima.
Harga runcit, borong maksimum untuk vaksin COVID-19 Sinovac Sinopharm ditetapkan
Harga runcit dan borong maksimum bagi dua produk vaksin COVID-19 jenama CoronaVac keluaran Sinovac dan Covilo keluaran Sinopharm akan ditetapkan berkuat kuasa Sabtu ini (15 Jan).
Tiga dos vaksin Sinovac mampu beri 94 peratus perlindungan terhadap varian Omicron
Kajian terbaharu menunjukkan tiga dos vaksin keluaran syarikat biotech Sinovac mampu menghasilkan antibodi peneutralan sebanyak 94 peratus terhadap varian COVID-19 Omicron.
KKM kumpul 663 sampel bagi kajian vaksin Sinovac kanak-kanak
Kementerian Kesihatan (KKM) telah mengumpul 663 sampel di seluruh negara untuk kajian bagi menentukan sama ada vaksin Sinovac sesuai diberikan kepada golongan kanak-kanak berusia tiga hingga 11 tahun.
Vaksin COVID-19: Pejabat Kesihatan Tawau sasar 30,000 penerima dos penggalak
Jumlah itu terdiri daripada penerima vaksin Sinovac dan Pfizer-BioNTech daripada golongan warga emas.
Vaksin COVID-19: Hong Kong turunkan had umur ambil vaksin mulai usia 3 tahun
Remaja berumur 12 hingga 17 tahun akan diberi keutamaan untuk menerima vaksin CoronaVac.
Ambil dos penggalak, ikuti kawalan wabak
Perkembangan situasi pandemik di dunia kini telah membuktikan pentingnya penggunaan dos penggalak.
Sinovac, Astrazeneca dipertimbang sebagai dos penggalak - Khairy
Kementerian Kesihatan (KKM) sedang mempertimbangkan vaksin Sinovac dan AstraZeneca digunakan untuk suntikan dos penggalak, kata menteri berkenaan Khairy Jamaluddin.